The need for a modernized approach to prevention of bovine papillomas is well-recognized among cattlemen and veterinarians. Historically, wart-extract vaccines have been inconsistent in reliability, supply, and in relation to risks of transmission of adventitious agents.
Cambridge Technologies ahs completed a pair of studies that show a reasonable expectation of efficacy (REE) for a Wart Vaccine, Killed Baculovirus Vector Vaccine. Due to the conditional nature of the product license, further investigation into product efficacy has not yet been completed.
The first study used a pseudovirus serum neutralization (pSN) assay to demonstrate the production of pSN neutralizing antibodies of > 1:640 in vaccinated calves, while unvaccinated placebo calves remained seronegative. No papillomas were detected at any time on any enrolled animal. Additionally, no systemic adverse reactions to vaccine administration nor any injection site reactions were noted in any calves.
A supplemental challenge study confirmed REE when used to vaccinate calves three months of age or older, as an aid in the control of bovine papillomavirus (warts). All of the calves from the prior study, including a mix of both vaccinates and unvaccinated controls, were intradermally challenged. All were co-mingled, and the only animals to develop warts were the five originally placebo-vaccinated subjects.
These studies were submitted to the USDA CVB as part of the process for receiving a conditional license for the vaccine.
Click Here for a complete report of the two REE studies conducted on this product.